<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">4524</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"> http://dx.doi.org/10.31782/IJCRR.2022.141210</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>Pleurotus citrinopileatus Extracts in HepG2 Cancer Cell Study&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Preethy</surname><given-names>Saroja</given-names></name></contrib><contrib contrib-type="author"><name><surname>Anbuselvi</surname><given-names/></name></contrib></contrib-group><pub-date pub-type="ppub"><day>17</day><month>06</month><year>2022</year></pub-date><volume>2)</volume><issue/><fpage>65</fpage><lpage>69</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Introduction: Pleurotus citrinopileatus is a mushroom with n-number of biomolecules expressing both nutraceutical and pharmaceutical qualities. In recent years, there are many medicinal properties of the mushroom brought to light, be it the biomolecules that inhibits fat-induced weight gain; cancer treatments for hepatoma, colon or HIV-1 reverse transcriptase inhibitory activity by novel lectins present in it. Objective: The present study is to find the degree of cell damage in HepG2 cancer cell lines caused by the extracts of Pleurotus citrinopileatus. Method: Herein, we are going to compare the level of cell damage caused by acetone, ethanol and aqueous extracts of Pleurotus citrinopileatus using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. Result: Acetone extracts of the mushroom showed higher cell damage in HepG2 cell line, indicated by MTT assay with the half-maximal inhibitory concentration (IC50) value of 37.03__ampersandsignmicro;g/ml, compared to the ethanolic and aqueous extracts of Pleurotus citrinopileatus. Conclusion: The acetone extract appears to possess biologically active compounds that might help reduce the viable cancer cells. If used as an adjuvant drug with cisplatin can reduce the effects caused by it and activate P53 action. Novelty: Further study on the biomolecules present in oyster mushrooms can give us an insight into the apoptotic behavior of cancer cells.&#13;
</p></abstract><kwd-group><kwd>Acetone</kwd><kwd> Aqueous extract</kwd><kwd> Cell damage</kwd><kwd> Cell viability</kwd><kwd> Ethanol</kwd><kwd> Pleurotus citrinopileatus</kwd><kwd> Chemo-embolization</kwd></kwd-group></article-meta></front></article>
